Member login

Forgot Password?
Return to login
Back to News index

BBA response to CMA announcement

Warwick Smith, Director General of the British Biosimilars Association (BBA), said:

“It would be inappropriate to comment specifically on the provisional decision taken by the Competitions and Markets Authority with regard to MSD allegedly operating an anti-competitive discount scheme for its medicine Remicade. However, any activity which artificially restricts competition or impacts pricing to the detriment of patients must be examined. Biosimilar medicines offer a fantastic opportunity to treat more patients for less money allowing savings to be ploughed back into frontline services.”